continuation of ceritinib beyond disease progression in alk-positive nsclc
Published 8 years ago • 149 plays • Length 0:39Download video MP4
Download video MP3
Similar videos
-
2:00
updated data from phase 2 study of alectinib in alk–positive non–small–cell lung cancer
-
5:15
results of ascend-4 trial of ceritinib versus chemotherapy in alk nsclc patients
-
6:51
progression in alk nsclc after frontline therapy
-
1:23
ascend-1 and ascend-2: ceritinib for alk-rearranged nsclc and baseline brain metastases
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
5:19
ascend-5: ceritinib for alk positive nsclc previously treated with crizotinib
-
5:52
ceritinib and alectinib in relapsed alk nsclc
-
5:52
alk positive forum disease progression xalkori
-
3:53
how to maximize clinical benefits for patients with alk-positive non-small cell lung cancer
-
6:47
upfront use of ceritinib in alk nsclc
-
1:16
rationale for evaluating ceritinib in alk-positive patients with nsclc
-
6:37
ascend-4: upfront ceritinib in alk-rearranged nsclc
-
6:12
experience with ceritinib for alk nsclc
-
6:04
case study: progression on alk inhibitors in nsclc
-
1:21
nice approval of brigatinib in alk-positive nsclc
-
1:22
assessing the efficacy of alectinib versus crizotinib in alk-positive nsclc
-
1:48
dr. chow on the use of ceritinib in alk nsclc metastatic to the brain
-
3:57
ascend-8: safety data of ceritinib with or without food in nsclc
-
4:15
nice approval: brigatinib in alk nsclc